Brief: Checkpoint Therapeutics Announces Initiation Of Conterno Phase 3 Trial Of Cosibelimab Combined With Chemotherapy In Patients With First-Line Non-Squamous Non-Small Cell Lung Cancer
08/12/2021 13:52
Dec 8 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES INITIATION OF CONTERNO
PHASE 3
TRIAL OF COSIBELIMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH
FIRST-LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX5MvcQX
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say